Literature DB >> 14668720

Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients.

Tina W F Yen1, Suzanne E Shapiro, Robert F Gagel, Steven I Sherman, Jeffrey E Lee, Douglas B Evans.   

Abstract

BACKGROUND: The surgical management and follow-up strategy in patients with medullary thyroid carcinoma (MTC) remain controversial because of the lack of data on the natural history of these tumors and their patterns of progression.
METHODS: We reviewed the records of all patients who underwent a cervical operation for MTC between 1991 and 2002. Compartment-oriented surgery (COS) was performed to minimize the risk of cervical recurrence.
RESULTS: We identified 92 consecutive patients who underwent a cervical operation for MTC: 80 had invasive MTC, and 12 had C-cell hyperplasia after prophylactic thyroidectomy for familial MTC. Ten (13%) of the 80 patients with invasive MTC presented with distant metastases and underwent COS to achieve local-regional control; cervical recurrence developed in none, but three have died of MTC. The remaining 70 patients underwent COS for primary (n=23) or recurrent (n=47) MTC. Disease recurred in 18 (26%) of these 70 patients at a median follow-up of 35 months, with 10 (14%) of the recurrences being cervical. Recurrent disease was associated with a basal calcitonin level of >250 pg/mL in all but four patients, two of whom showed tumor dedifferentiation. In contrast, only 5 (11%) patients without evidence of recurrence had basal calcitonin levels of >250 pg/mL at last follow-up.
CONCLUSIONS: Complete COS minimizes cervical recurrence. Radiographic evidence of recurrent disease is unlikely when the calcitonin level is < or =250 pg/mL. These data could be used to develop a logical, cost-effective treatment and follow-up strategy for patients with MTC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668720     DOI: 10.1016/s0039-6060(03)00408-2

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 2.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

3.  The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.

Authors:  Trond Velde Bogsrud; Dimitrios Karantanis; Mark A Nathan; Brian P Mullan; Gregory A Wiseman; Jan L Kasperbauer; Carl C Reading; Trine Björo; Ian D Hay; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

4.  Results of Surgical Therapy in Patients with Medullary Thyroid Carcinoma.

Authors:  Mihaela Vlad; Ioana Zosin; Bogdan Timar; Fulger Lazar; Adrian Vlad; Romulus Timar; Marioara Cornianu
Journal:  Indian J Surg       Date:  2015-11-12       Impact factor: 0.656

Review 5.  Evidence-based approach to the management of sporadic medullary thyroid carcinoma.

Authors:  Jeffrey F Moley; Elizabeth A Fialkowski
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

6.  Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma.

Authors:  Hyunju Park; So Young Park; Jun Park; Jun Ho Choe; Man Ki Chung; Sook-Young Woo; Joon Young Choi; Sun Wook Kim; Jae Hoon Chung; Tae Hyuk Kim
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-05       Impact factor: 5.555

7.  Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases.

Authors:  Lenine G Brandão; Beatriz G Cavalheiro; Consuelo R Junqueira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

8.  Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.

Authors:  Mohamed Abdelgadir Adam; Samantha Thomas; Sanziana A Roman; Terry Hyslop; Julie A Sosa
Journal:  JAMA Surg       Date:  2017-09-01       Impact factor: 14.766

9.  Nodal disease burden and outcome of medullary thyroid carcinoma.

Authors:  Lindsey E Moses; Jamie R Oliver; Janine M Rotsides; Qianhui Shao; Kepal N Patel; Luc G T Morris; Babak Givi
Journal:  Head Neck       Date:  2020-10-27       Impact factor: 3.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.